or Try an Advanced Search...

    Technical Analysis for EQ - Equillium, Inc.

    Grade Last Price % Change Price Change
    D 1.55 0.65% 0.01
    EQ closed unchanged on Wednesday, May 15, 2024, on 31 percent of normal volume.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Down Down
    Historical EQ trend table...
    Date Alert Name Type % Chg
    20 DMA Resistance Bearish 0.65%
    Doji - Bullish? Reversal 0.65%
    Bearish Engulfing Bearish 1.31%
    Fell Below 20 DMA Bearish 1.31%
    Earnings Movers Other 1.31%
    Outside Day Range Expansion 1.31%
    Gapped Up Strength 1.31%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -13.89%
    Crossed Above 20 DMA Bullish -13.89%
    Stochastic Reached Overbought Strength -13.89%
    Older End-of-Day Signals for EQ ...

       Recent Intraday Alerts

    Alert Time
    20 DMA Resistance about 2 hours ago
    10 DMA Resistance about 2 hours ago
    Up 5% about 2 hours ago
    60 Minute Opening Range Breakout about 3 hours ago
    Up 3% about 3 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    EQ Chart by TradingView
    Basic chart:

    Profile

    Equillium is a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium’s initial product candidate, EQ001 (itolizumab), is a clinical-stage, first-in-class monocolonal antibody that selectively targets the novel immune checkpoint receptor CD6 and is designed to modulate T cells that drive immuno-inflammation. Itolizumab is a clinically-validated therapeutic with a favorable safety and tolerability profile. Equillium plans to advance EQ001 into clinical development in multiple indications of high unmet medical need and believes EQ001 has the potential to be a best-in-class disease modifying therapeutic.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Biology Immunology Immune System Clinical Development Inflammation Monoclonal Antibody Antibody Autoimmunity Glycoproteins Immune Checkpoint Inflammatory Disorders

    Is EQ a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 14 Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
    May 9 Equillium GAAP EPS of -$0.08, revenue of $10.7M
    May 9 Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates
    May 9 Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights
    May 7 Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists
    May 2 We're Keeping An Eye On Equillium's (NASDAQ:EQ) Cash Burn Rate
    Apr 3 Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    Apr 1 5 Stocks That More Than Doubled in Q1 With More Gains Ahead
    Apr 1 Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis
    Mar 25 Equillium GAAP EPS of -$0.07, revenue of $9.2M
    See more EQ news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.25
    52 Week Low 0.45
    Average Volume 160,912
    200-Day Moving Average 1.18
    50-Day Moving Average 2.04
    20-Day Moving Average 1.65
    10-Day Moving Average 1.64
    Average True Range 0.20
    RSI (14) 40.83
    ADX 25.94
    +DI 14.23
    -DI 22.13
    Chandelier Exit (Long, 3 ATRs) 1.28
    Chandelier Exit (Short, 3 ATRs) 1.93
    Upper Bollinger Bands 1.86
    Lower Bollinger Band 1.43
    Percent B (%b) 0.25
    BandWidth 26.00
    MACD Line -0.11
    MACD Signal Line -0.11
    MACD Histogram 0.0073
    Fundamentals Value
    Market Cap 54.08 Million
    Num Shares 35.1 Million
    EPS -0.22
    Price-to-Earnings (P/E) Ratio -7.00
    Price-to-Sales 1.27
    Price-to-Book 2.24
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.78
    Resistance 3 (R3) 1.79 1.73 1.74
    Resistance 2 (R2) 1.73 1.67 1.72 1.73
    Resistance 1 (R1) 1.63 1.63 1.60 1.62 1.71
    Pivot Point 1.57 1.57 1.55 1.56 1.57
    Support 1 (S1) 1.47 1.51 1.44 1.46 1.37
    Support 2 (S2) 1.41 1.47 1.40 1.35
    Support 3 (S3) 1.32 1.41 1.34
    Support 4 (S4) 1.30